Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery.

Zoe Tasma Andrew Siow Paul W R Harris Margaret A Brimble Debbie L Hay Christopher S Walker

Published in: British journal of pharmacology (2021)

The distinct pharmacological profile displayed by the PAC1s receptor suggests that it can act as a dual receptor for VIP and PACAP. Furthermore, the effectiveness of blocking a signalling pathway can be influenced by which endogenous PACAP family agonist is present. These effects have potential implications for the development and effectiveness of drugs targeting the PACAP system.

Keyphrases

drug discovery
randomized controlled trial
systematic review
cancer therapy
binding protein
climate change
drug induced